Patent ID: 7125681
Filing Date: 2006-10-24
Classification: G01N

Abstract:
1. A method for determining that a patient suffers from a cancer characterized by aberrant expression of a cancer-testis (CT) antigen, consisting of: i) contacting a urine containing sample from a patient that is believed to suffer from said cancer with a cancer-testis (CT) antigen that specifically binds to an antibody present in said urine and characteristic of said cancer, under conditions favoring complex formation between the cancer-testis (CT) antigen and the antibody; and ii) detecting the complex between the cancer-testis (CT) antigen and the antibody present in said urine, wherein presence of the antibody, as indicated by formation and detection of the complex indicates that the patient suffers from said cancer, wherein the cancer-testis (CT) antigen is NY-ESO-1 (SEQ ID NO:1), the protein encoded by the nucleic acid sequence of SEQ ID NO: 2 (SCP-1) or the protein encoded by the nucleic acid sequence of SEQ ID NO: 3 (clone 18CGI1F2).